Accure Therapeutics awarded a total of $1.6M in grants from The Michael J. Fox Foundation and Fonds National de Recherche de Luxembourg to bring first-in-class drug for Parkinson’s disease to clinical trials
Accure to complete required preclinical studies to file IND application for ACT-02 program in 2026 Fonds National de Recherche (FNR) grant will ...
Read moreDetails













